Sebacic Acid

Sebacic Acid

SCHEMBL689154

Cl.Cl.O=C(O)CCCCCCCCC(=O)O

nearest known ligand 0.92

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Sebacic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG known ✓ P37231 6/20 0.67
HDAC11 known ✓ Q96DB2 5/20 0.67
ESR1 known ✓ P03372 1/20 0.67
PDE4A known ✓ P27815 1/20 0.67
PDE3A known ✓ Q14432 1/20 0.67
SLC6A2 known ✓ P23975 1/20 0.67
SLC6A3 known ✓ Q01959 1/20 0.67
TSHR P16473 5/20 0.92
LMNA P02545 3/20 0.92
NFKB1 P19838 1/20 0.92
PMP22 Q01453 1/20 0.92
SLC22A6 Q4U2R8 2/20 0.71
GPR84 Q9NQS5 8/20 0.71
FFAR1 O14842 2/20 0.71
FFAR4 Q5NUL3 2/20 0.71
PPARD Q03181 6/20 0.67
PPARA Q07869 6/20 0.67
ALDH1A1 P00352 3/20 0.67
TLR2 O60603 2/20 0.67
TDP1 Q9NUW8 2/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL688374 1.00 TSHR (0.92) TSHRLMNANFKB1PMP22SLC22A6
Sebacic Acid SCHEMBL7717227 1.00 TSHR (0.92) TSHRLMNANFKB1PMP22SLC22A6
Azelaic Acid SCHEMBL4157618 1.00 TSHR (0.92) TSHRLMNANFKB1PMP22SLC22A6
Hydrochloric Acid SCHEMBL8921154 1.00 TSHR (0.92) TSHRLMNANFKB1PMP22SLC22A6
Sebacic Acid SCHEMBL14809040 1.00 TSHR (0.92) TSHRLMNANFKB1PMP22SLC22A6
Hydrochloric Acid SCHEMBL19210205 1.00 TSHR (0.92) TSHRLMNANFKB1PMP22SLC22A6
Sebacic Acid SCHEMBL14809563 1.00 TSHR (0.92) TSHRLMNANFKB1PMP22SLC22A6
Hydrochloric Acid SCHEMBL8922192 1.00 TSHR (0.92) TSHRLMNANFKB1PMP22SLC22A6
Hydrochloric Acid SCHEMBL7717229 1.00 TSHR (0.92) TSHRLMNANFKB1PMP22SLC22A6
Hydrochloric Acid SCHEMBL8923793 1.00 TSHR (0.92) TSHRLMNANFKB1PMP22SLC22A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 361 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114995061-B Low-water-absorption positive photosensitive resin composition and preparation method and application thereof 明士(北京)新材料开发有限公司 2022-11-01 CN claimed
CN-115220305-A Positive photosensitive resin composition and preparation method and application thereof 明士(北京)新材料开发有限公司 2022-10-21 CN claimed
CN-114995061-A Low-water-absorption positive photosensitive resin composition and preparation method and application thereof 明士(北京)新材料开发有限公司 2022-09-02 CN claimed
CN-114272212-A Rac1 inhibitor nano particle targeting prostate cancer, preparation method and application 中山大学孙逸仙纪念医院 2022-04-05 CN claimed
CN-110461498-B Polyurethane-curable organic binder for casting molds, and molding sand composition and casting mold obtained using same 旭有机材株式会社 2021-10-08 CN claimed
US-10202333-B2 Aqueous solution containing bis(N epsilon lauroyllysine)dicarboxylic acid diamide and/or salt thereof, and method for producing same AJINOMOTO CO., INC. (JP) 2019-02-12 US claimed
US-20170260127-A1 AQUEOUS SOLUTION CONTAINING BIS(N EPSILON LAUROYLLYSINE)DICARBOXYLIC ACID DIAMIDE AND/OR SALT THEREOF, AND METHOD FOR PRODUCING SAME AJINOMOTO CO., INC. (JP) 2017-09-14 US claimed
US-9133279-B2 Cross-linked polymer of carbohydrate, notably based on polysaccharides, and/or on oligosaccharides and/or on polyols BASF BEAUTY CARE SOLUTIONS FRANCE S.A.S. (FR) 2015-09-15 US claimed
US-20060188465-A1 Cross-linked polymer of carbohydrate, notably based on polysaccharides, and/or on oligosaccharides and/or on polyols ENGELHARD LYON (FR) 2006-08-24 US claimed
EP-0785952-B1 GRAFT CERAMIDE HAVING AN ANTI-ELASTASE PROPERTY FABRE PIERRE DERMO COSMETIQUE (FR) 1998-07-15 EP claimed
US-5739256-A Method for making multidimensional polyester oligomers THE BOEING COMPANY (US) 1998-04-14 US claimed
US-4277576-A Preparation of modified polymers of N-vinylpyrrolid-2-one and their use for the preparation of polymers interrupted by bridge members BASF AKTIENGESELLSCHAFT (DE) 1981-07-07 US claimed
US-4100116-A AMINATION BAYER AKTIENGESELLSCHAFT (DE) 1978-07-11 US claimed
JP-61192785-A None JP disclosed
CN-117651742-B Compounds using natural pigments DIC株式会社 2026-05-12 CN disclosed
US-20260117059-A1 CURABLE RESIN, CURABLE RESIN COMPOSITION, CURED PRODUCT, PREPREG, LAMINATE, AND SEMICONDUCTOR SUBSTRATE NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2026-04-30 US disclosed
US-4079041-A CONTAINING PHOTOSENSITIVE MALEIMIDO GROUPS, PHOTOCURABLE CIBA-GEIGY CORPORATION (US) 1978-03-14 US disclosed
US-4066616-A ORGANIC POLYMERS CIBA-GEIGY CORPORATION (US) 1978-01-03 US disclosed
US-3994952-A Anti-tricyclo[6.4.0.0.2,7 ]1,4,7,10-tetracarboxy-2,5,8,11-tetrahydroxy-dodeca-4,10-diene and esters thereof, a process for their preparation, and their use in preparing linear polyesters CIBA-GEIGY CORPORATION (US) 1976-11-30 US disclosed
US-3956298-A POLYMER STABILIZERS CIBA-GEIGY CORPORATION (US) 1976-05-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260117059-A1 CURABLE RESIN, CURABLE RESIN COMPOSITION, CURED PRODUCT, PREPREG, LAMINATE, AND SEMICONDUCTOR SUBSTRATE RAD51, ASH2L, H1-0 PPARG 3637/4885HDAC11 1482/4885ESR1 227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.